Call Us Today:
949.200.1600

Photodynamic Therapy (PDT)

Home > Treatment > Nonsurgical Treatment > Photodynamic Therapy (PDT)

Non-surgical-skin-cancer-treatment-options-photodynamic-therapy-PDT

About Photodynamic Therapy (PDT)

Photodynamic therapy (PDT) is a unique treatment with clear benefits in non-melanoma skin cancers and precancerous lesions. It is noninvasive, selectively treats abnormal cells, and is relatively inexpensive. Despite these accolades, it is an orphan treatment often rejected for other treatment options.

PDT uses porphyrin molecules that have selective penetration of abnormal epidermis. Activated by specific light frequencies, these molecules create a cytotoxic effect, selectively injuring the neoplastic lesions. Two such porphyrins have been utilized – the more common aminolevulinate (ALA, Levulan Kerastick) and possibly the more effective methyl aminolevulinate (MAL, Metvix). FDA-approved only for treatment actinic keratoses, this technology has been applied to treatment of squamous cell carcinoma in situ (SCCis) and superficial basal cell carcinomas (sBCC).

Treatment of MAL-PDT is delivered after 3 hours of MAL cream under occlusion, followed by 15 minutes of red light exposure. More common in the US, ALA-PDT uses blue light frequencies. Burning and stinging occur mostly during illumination but can persist for a day. Treatment is usually repeated 1 week later and occasionally in 3 months if complete responses is not achieved. Surface debridement or curettage can improve penetration and efficacy.

Summarizing various studies demonstrates efficacy of PDT for AK at 85-90% complete response. Bowen’s disease is cleared in 90% of cases but at 2 years that number is reduced to 68%. Superficial BCC (sBCC) and thin nodular BCC (nBCC) are cured in 75-95% of cases after 3-5 years in various studies. Thick BCC are cleared in 80-85% of cases at 2-4 years.

It is fair to say that MAL-PDT achieves a long-term cure for BCC in 80-95% of cases, with the median falling above 85%. Although AK’s achieve a similar success, the available studies for Bowen’s disease show worse long-term cure rate than other pathologies. Cosmetic outcomes are found to be superior to all other treatments.

With this data in hand, it is no wonder that British studies form the NHS hospitals and clinics recommend PDT as “the treatment of choice” for primary sBCC in a low risk site (not in central face) that are 2cm and “generally good choice” if < 2cm. They also claim PDT as “generally good choice” in recurrent sBCC in low risk sites. The next category of “fair choice” is reserved for primary nBCC < 2cm in low risk site, primary sBCC < 2cm in high risk site, and primary sBCC 2cm in high risk site.

There are a few innovative applications for photodynamic therapy described. PDT has been successfully applied in Basal Cell Nevus Syndrome patients. Unique delivery methods have included intralesional ALA injection and an ALA patch for specific lesions. In addition to fluorescent and LED light sources, IPL (Intense Pulsed Light) has been utilized with success as stand alone and in addition to the traditional light sources.

The unique advantages of photodynamic therapy for skin cancers is the ability to treat large areas of field cancerization, the relatively low cost, and the superb cosmetic results. Its under utilization as a modality for non-melanoma skin cancer management in the United States is likely related to economics of the treatment and patient expectations.

Related Posts

PDT Across the Atlantic and Medical Economics

April 16, 2013

Does medical economics bias the community standards for treatment of skin cancers? If the answer is yes, then photodynamic therapy serves as an illustrative example of this bias. Private practice dermatology in the US and National Health Service of UK are practice settings with significantly different economics and also different treatment goals. The one’s is…

Read More

Diagnosis change: AFX to Pleomorphic Sarcoma of Neck

October 24, 2017

  HISTORY 93-year-old man presents with an incidentally discovered left neck mass during evaluation of a left ear SCC. Initial biopsy on 9-5-17 showed atypical fibroxanthoma. Excision of the left neck lesion with 5 mm margins on 9-26-17 revealed malignant spindle and epithelioid cell neoplasm consistent with pleomorphic dermal sarcoma. Deep and peripheral margins were…

Read More

POST NASAL RECONSTRUCTION ISCHEMIC COMPLICATIONS

August 23, 2017

HISTORY 75-year-old man presents with a history of recurrent basal cell carcinoma of the nasal tip, previously treated with liquid nitrogen and excised 3-5 years ago. Mohs surgery was performed 7-10-2017 with a 3.2 x 3 cm defect extending from the nasal tip and ala to the mid dorsum. Reconstruction was performed with an extended…

Read More

STUMP and MelTUMP

October 31, 2012

Ambiguous melanocytic lesions – those with histopathologic findings without a diagnostic consensus – are divided into thin and thick tumors. Thin lesions appear as dysplastic nevi and have a potential of being part of melanoma in situ or superficial spreading melanoma. We have explored diagnostic and therapeutic considerations of the thin lesions in a previous…

Read More

ALAR ISLAND FLAP

May 15, 2017

Discussion This month’s reconstructive case series addresses a small alar island flap for reconstruction of smaller defects of the ala. The alar island flap is based on lateral nasal artery and alar artery arising from the angular artery of the face. Wide release of the flap is necessary both in subcutaneous plane and in submuscular plane separating if…

Read More

Smoothened and Patched and Sonic Hedgehogs – From Cyclopic Sheep to Targeted Basal Cell Carcinoma Treatment

October 18, 2011

What does Frizzled, Frazzled, Dishevelled, and Smoothened have to do with the Sonic Hedgehog? These are some of the humorously named genes in Drosophila fruit flies that also happened to be expressed in humans. Besides adding character to the genes, these names occasionally reflect the traits they describe. Hedgehog (Hh) gene is part of the…

Read More

STAY UP TO DATE

Sign up for our newsletter!

Collaborate on a Patient

Coordinate a Mohs procedure with our surgeons. Operate at our surgery center.

PRESENT AT SCARS TUMOR CONFERENCE

SCARS Foundation Monthly Skin Cancer Conference is CME Accredited.